标题：Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
作者：Yu, Qing; Wang, Wen-Xia
作者机构：[Yu, Qing; Wang, Wen-Xia] Shandong Univ, Sch & Hosp Stomatol, Dept Periodontol, Shandong Key Lab Oral Tissue Regenerat,Shandong E, 44-1 Wenhua Rd West 更多
通讯作者地址：Wang, WX (corresponding author), Shandong Univ, Sch & Hosp Stomatol, Dept Periodontol, Shandong Key Lab Oral Tissue Regenerat,Shandong E, 44-1 Wenhua 更多
来源：WORLD JOURNAL OF CLINICAL CASES
关键词：Camrelizumab; Adverse effects; Reactive capillary hemangioma; Gingiva;; Case report
摘要：BACKGROUND Oncologic immunotherapy is attracting attention as an effective strategy for cancer treatment. Currently, there are two kinds of inhibitors: Anti-PD-1 antibodies and anti-PD-L1 antibodies. These inhibitors have shown significant implications in improving the outcomes of certain cancer types in recent years. However, along with its effectiveness, adverse events cannot be ignored. As an anti-PD-1 antibody, camrelizumab (SHR-1210) has some side effects in tumor immunotherapy. The most common adverse event is reactive capillary hemangioma. While it is widely reported to occur in the skin, gingival reactive capillary hemangioma is rarely reported.; CASE SUMMARY A 54-year-old man complained of gingival overgrowth on the anterior aspect of the maxilla and mandible for more than 6 mo. He had been placed on SHR-1210 for lung cancer for 7 mo. A gingival mass extending from canine to canine was noted on the lingual surfaces of the mandible. Gingival enlargement was noted in the front teeth. A clinical diagnosis of gingival reactive capillary hemangioma and chronic periodontitis was made. The treatment involved a complex local treatment (repeated local applications of an antibiotic paste, scaling and root planning, and surgery). The excised tissue was sent for histopathological examination, which confirmed the diagnosis of capillary hemangioma. After the operation, most of the gingival enlargement was reduced. At the 2-mo follow-up, it was noted that the gingival overgrowth was immediately reduced after the replacement of the anti-PD-1 agent with an anti-PD-L1 agent.; CONCLUSION As the prescription for SHR-1210 has increased considerably in recent years, the occurrence of its possible side effects, including gingival reactive capillary hemangioma, has increased. It is recommended that regular oral examinations be performed before and during the treatment of tumors with SHR-1210.